title: [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
abstract: Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.
authors.affiliation: Copenhagen Prostate Cancer Center, Rigshospitalet, Tagensvej 20, 2200 København N. andreasroder@gmail.com.
authors.forename: Sissal Sigmundsdòttir
authors.initials: SS
authors.lastname: Djurhuus
authors.forename: Klaus
authors.initials: K
authors.lastname: Brasso
authors.forename: Kasper Drimer
authors.initials: KD
authors.lastname: Berg
authors.forename: Peter
authors.initials: P
authors.lastname: Iversen
authors.forename: Martin Andreas
authors.initials: MA
authors.lastname: Røder
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000276:immunology / Q000628:therapy*; D014020:Tissue Extracts / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; C588274:PROSTVAC; D014020:Tissue Extracts; C511774:sipuleucel-T